Principles of Transparency and Best Practice of Scholarly Publishing (4th edition)
Sixteen check list of compliance of the journal to the Principles of Transparency and Best Practice in Scholarly Publishing published September 15 2022 (joint statement by Committee on Publication Ethics (COPE), Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishing Association (OASPA), and the World Association of Medical Editors (WAME); (https://doaj.org/apply/transparency) was as follows:
| Journal Content | Journal Practices | Organisation | Business Practices |
|---|---|---|---|
|
1. Name of Journal 2. Website 3. Journal Schedule 4. Archiving 5. Copyright 6. Licensing |
7. Publication Ethics and Related Editorial Policies 8. Peer Review 9. Access |
10. Ownership and Management 11. Advisory Body 12. Editorial Team and Contact Information |
13. Author Fees 14. Other Revenue 15. Advertising 16. Direct Marketing |
1. Name of Journal
The official journal title is Kawasaki Disease (herein “KD”), the abbreviation of ISO is Kawasaki Dis. (eISSN 2983-3183)
2. Website
The URL of official journal web site is https://www.e-kd.org.
The KD managing team endeavors to make a good website. Our website demonstrates that care has been taken to ensure high ethical and professional standards. It does not contain any misleading information, including any attempt to mimic another journal/publisher’s site.
- Aims and scope: https://www.e-kd.org/info/aim
- Readership: https://www.e-kd.org/info/readership
- Types of Manuscripts: https://www.e-kd.org/author/guideline#type_of_manuscript
- Authoship Criteria: https://www.e-kd.org/author/ethics#authorship
- eISSN: 2983-3183
3. Publishing schedule
Kawasaki disease is published biannually (June 30 and December 31)
4. Archiving
The journal is accessible at official website(e-kd.org), Google Scholar (https://scholar.google.co.kr), National Assembly Library of Korea (https://www.nanet.go.kr), and National Library of Korea (http://nl.go.kr) in the event the journal is no longer published.
5. Copyright
All published papers become the permanent property of the Korean Society of Kawasaki Disease. Copyrights of all published materials are owned by the Korean Society of Kawasaki Disease and must not be published elsewhere without written permission. The form of copyright transfer form is available from the journal website and submission system(https://www.e-kd.org/author/copyright_transfer).
6. Licensing
All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
7. Publication ethics and related editorial policies.
The journal follows the Guideline on Good Publication of COPE (https://publicationethics.org) and Recommendations of International Committee of Medical Journal Editors (https://www.icmje.org/recommendations).
Our publication ethics and related editorial policies are displayed on Instruction for Authors (Research and publication ethics) tab (https://www.e-kd.org/author/ethics) of the journal webite.
The Editorial Board of KD carefully examines whether all submitted manuscripts abide the ethical guidelines of ICMJE and COPE. The published articles should include the statements of conflict of interest, author's contribution, Institutional Review Board, informed consent, and human/animal rights.
When the journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by COPE (https://publicationethics.org/resources/flowcharts). The Editorial Board of KD will discuss the suspected cases and reach a decision. KD will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
8. Peer Review
The KD has on online submission and peer review system at https://submission.e-kd.org.
The submitted manuscript will first be evaluated at the editorial board regarding the possibility of plagiarism, completeness of the submitted materials, and their suitability to KD. Prior to the peer review, the editorial board can reject manuscripts for misconduct, or request the authors for explanation. Manuscripts may be returned to the authors at this stage if they have serious flaws or are not suitable for KD.
Submitted manuscripts will generally be reviewed by the editors and two peer reviewers. The reviewers make suggestions to the editorial board.
KD performs double-blinded peer review of the submitted manuscripts. Neither the peer reviewers nor the authors are revealed to each other.
The authors can monitor the progress of the manuscript throughout the review process at the submission system (https://submission.e-kd.org/).
The first review is finished within 60 days after the first submission. Reviewers consider the originality, scientific importance, study design, methodology, brevity in expression, priority for publication, and potential for revision. Reviewers should provide constructive criticism on the parts requiring revision. Submitted manuscripts will be rendered one of the following decisions: Accept, Minor Revisions, Major Revisions, and Reject. A revision needs to be submitted within 60 days of the decision. Otherwise, the manuscript is regarded as a new submission.
- All submitted manuscripts are subject to the Turnitin, and the editorial office can reject the manuscripts suspected of plagiarism.
- Manuscripts for case reports regarding diseases that have already been reported cannot be published. However, they may be published after proper review process if they contain the discussion over unknown aspects of the disease, new diagnostic and therapeutic modalities, and unknown associated diseases.
- If manuscripts regarding drugs or equipment have a potential for commercial use, the editorial office can consult proper specialists on them.
- Manuscripts containing the contents which have already been rejected by KD can be published only if substantially improved.
- The editorial board reserves the right to make corrections to literary and technical flaws found in the accepted manuscripts after proper communication with the corresponding authors.
- The editorial board can refer the editing process to outsourced manuscript editors.
The decision to accept a manuscript is not based solely on the scientific validity and originality; other factors are considered, including the extent and importance of new information in the paper as compared with that in other papers being considered, the journal's need to represent a wide range of topics, the overall suitability for KD, and research and publication ethics.
Decision letters usually, but not always, convey all factors considered for a particular decision. Occasionally, reviewers’ comments may appear to be inconsistent with the decision, which takes into consideration reviewers' comments as well as the additional factors listed above.
9. Access
KD is an open access journal. A free full-text service, both in XML and PDF formats, is available at the official websites (https://www.e-kd.org).
10. Ownership and Management
This journal is owned by the publisher, the Korean Society of Kawasaki Disease (https://www.kawasaki.or.kr). The journal is managed by the Management Team.
11. Advisory body
The advisory body is the journal's editorial board. The full names and affiliations of the journal’s editors are displayed on the Editorial Board tab of the journal website. (https://www.e-kd.org/info/editorial_board)
12. Editorial Team and Contact Information
Editorial team is available from Editorial Board page at the front part of the journal.
Contact information: https://www.e-kd.org/info/contact
13. Author Fees
There is no author's submission fee or other publication related fee since every cost for the publication process is supported by the publisher.
14. Other Revenue
Revenue sources of journal are from the support of publisher (the Korean Society of Kawasaki Disease) and advertising rates.
15. Advertising
KD accepts advertisements. Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.
Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.
16. Direct Marketing
Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.